Abdera Therapeutics
Vancouver, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $142M
Overview
Developing next-generation targeted alpha-particle therapies for precision oncology.
Oncology
Technology Platform
A proprietary platform for developing targeted alpha therapies, combining tumor-specific targeting with stabilized alpha-emitting radioisotopes.
Funding History
1Total raised:$142M
Series A$142M
Opportunities
Potential to treat resistant and metastatic cancers with a highly potent and precise modality that is gaining significant clinical and commercial validation.
Risk Factors
Complex manufacturing, regulatory hurdles for novel radiopharmaceuticals, and securing a reliable supply of expensive alpha-emitting isotopes.
Competitive Landscape
Competes with other targeted radiopharmaceutical biotechs and large pharma (e.g., Novartis) in the expanding nuclear medicine oncology field.